Novavax (NVAX) said Tuesday that preliminary results from a real-world study showed that its COVID-19 vaccine targeting the JN.1 strain led to fewer and less severe reactogenicity symptoms compared with Pfizer-BioNTech's mRNA 2024-2025 vaccine.
The biotech company said the study, conducted in partnership with the University of Utah Health, showed that the impact of symptoms on daily activities, such as work and family responsibilities, was lower in patients receiving Novavax's vaccine.
Novovax said that, on average, recipients of its vaccine experienced 1.7 symptoms compared with 2.8 systemic symptoms in Pfizer-BioNTech recipients.
Additionally, the company said 43.8% of Pfizer-BioNTech recipients experienced at least one symptom of grade 2 or higher compared with 24.2% of Novavax recipients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。